CTOs on the Move

Cortexyme

www.cortexyme.com

 
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cortexyme.com
  • 269 East Grand Avenue
    South San Francisco, CA USA 94080
  • Phone: 415.910.5717

Executives

Name Title Contact Details

Funding

Cortexyme raised $15M on 01/06/2016
Cortexyme raised $76M on 05/31/2018
Cortexyme raised $125M on 02/05/2020

Similar Companies

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

DICE Therapeutics

Total Repair Express

Total Repair Express is a Hillsborough, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centocor

Tgs Technologies

Tgs Technologies, Llc is a Cranberry Twp, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.